Halozyme Therapeutics, Inc.

Fourth Quarter and FY 2023 Financial & Operating Results

NASDAQ: HALO

February 20, 2024

Halozyme

Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2024 guidance and longer term financial outlook through 2028) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales, and revenue durability and diversification), EBITDA, Adjusted EBITDA, non-GAAP diluted earnings-per-share, expected growth rates of the Company's partnered products, potential share repurchases and the Company's plans to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and potential to decrease treatment burden, infusion related reactions and healthcare system costs and enable new treatment sites. Forward-looking statements regarding the Company's business may also include potential growth driven by our partners' development and commercialization efforts (including anticipated ENHANZE® indication and product approvals and launches and the timing related to these events), projections for future sales revenue and market share of our collaborators' products, potential new or expanded ENHANZE® collaborations, collaborative targets and indications for ENHANZE® products, the potential for co-formulation patents to extend royalty payment periods and maintain royalty rates, and the Company's plans to develop a high volume auto-injector (including statements related to potential future development, approval and patient treatment benefits of a high volume auto-injector). These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners and product sales), expenditures and costs, unexpected delays in the execution of the Company's planned platform expansion or share repurchases, unexpected results or delays in the growth of the Company's ENHANZE® business (including as a result of unexpected conversion rates) or other proprietary product revenues, obtaining new co-formulation or proprietary intellectual property, or in the development, regulatory review or commercialization of our partners' ENHANZE® products, unexpected delays in the Company's plans to develop and commercialize a high volume auto-injector, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Non-GAAP Financial Measures:
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports Adjusted EBITDA, Adjusted EBITDA Margin and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. The Company does not provide reconciliations for forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, share based compensation expense and the effects of any discrete income tax items. Reconciliations between GAAP and non-GAAP financial measures are included in these materials.

Industry Leading Drug Delivery Platform Company

ENHANZE®

7 approved partnered products

Approved in **100+** countries

~800,000 patients have received ENHANZE®-enabled treatments

+

Small Volume Auto-Injector with Drug (SVAI)

1 approved proprietary SVAI

3 approved partner SVAI products

>40M devices supplied 2013-2023

+

Commercial Products

XYOSTED™
(testosterone enanthate) injection

Hylenex® recombinant
(hyaluronidase human injection)

Strong 2023 Results with Significant Growth Opportunities

$829M
Total Revenue
+26%

$448M
Royalty Revenue
+24%

$426M
Adjusted EBITDA
+19%

$2.77
Non-GAAP Diluted EPS
+25%

$400M
Deployed for Share Repurchases

- Broad Portfolio
- Multiple Revenue Streams
- Strong Pipeline
- Extensive Patent Estate

Operational and Commercial Achievements in 2023

Commercialization and Development Milestones

2023 Approvals

- VYVGART® Hytrulo (gMG) in U.S and EU
- Tecentriq® SC in UK

Resulting in 7 commercial ENHANZE® - enabled products in up to 100+ countries

Positive Phase 3 Data

- VYGART® Hytrulo (CIDP)
- Atezolizumab SC
- Ocrelizumab SC
- Nivolumab SC

Pipeline Advancements

- Positive Phase 1 data for amivantamab SC*
  - ✓ Supported dose selection
  - ✓ IRR 16% SC versus 67% IV
- ViiV: N6LS Phase 2b study initiation
- ViiV: Phase1 for undisclosed target

Innovation + Partnership Milestones

ENHANZE® + **Halozyme Auto-Injector Technology and Know-How** ❯

First HVAI delivering 10mLs in <30secs

ACUMEN

- Non-exclusive agreement
- Upfront payment
- Milestones
- Single-digit royalties

Halozyme

* Subcutaneous Amivantamab in Patients With Advanced Solid Malignancies: The PALOMA Study – Updated Safety and Confirmation of the Recommended Phase 2 Dose; ASCO 2023, Minchom et al

A De-Risked & Proven Business Model Positioned for Durable Revenue and EBITDA Growth



Revenue 2023 - 2024



Adjusted EBITDA 2023 - 2024



Revenue 2023 - 2028



Adjusted EBITDA 2023 - 2028

CAGR calculated from 2023 actual to 2028 midpoint.

Royalty Revenues

Annual Total Royalty Revenue

24% YoY Increase in 2023



Wave 2: Growth Drivers

DARZALEX SC/FASPRO® Revenue Growth Continues

Total DARZALEX® Sales IV+SC ($B) [1]



Growth Drivers

- Increase penetration into front line treatment
- Johnson & Johnson submitted sBLA to FDA seeking approval of DARZALEX *FASPRO*® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma on January 30th 2024

	Darzalex FASPRO-VRd[2]	VRD	
Estimated % patients with progression-free survival at 48 month	84.3%	67.7%	Hazard ratio for disease progression or death, 0.42; 95%confidence interval, 0.30 to 0.59; P<0.001);
% patients with complete response or better	87.9%	70%	P<0.001
MRD-negative status	75.2%	47.5%	P<0.001

Halozyme

[1] Analysts' consensus from Evaluate Ltd January 2024
[2] Sonneveld et al N Engl J Med 2024;390:301-13.

Wave 2: Growth Drivers
Phesgo® Growth Continues US and Ex-US

Phesgo® Reduces Administration Time and Costs

Treatment Option	Total Time
	~2.5-7.5 hours
 Phesgo	~20-38 minutes • 5-7 minutes treatment time

85% of patients preferred Phesgo® for subcutaneous administration over the intravenous formulation of Perjeta and Herceptin

Growth Drivers[1]

- New market launches
- Share gains in US and ex-US
  - 39% conversion[2]

2023 Phesgo® Sales	Sales (CHFm)	Growth CER
TOTAL	**1,120**	**64%**
US	423	48%
EU	534	52%
International	159	189%

[1] Roche Fourth Quarter 2023 Results
[2] Perjeta/Phesgo® conversion rate is based on volumes (vials) and includes 46 launch countries into account

Multiple Recent and Projected Product and Indication Launches Drive Near and Long-Term Royalty Revenue Growth



~$35B Projected Sales of Wave 3 Products (SC and IV) in 2028

Halozyme

Analysts' consensus from Evaluate Ltd January 2024

ENHANZE® Wave 4 Pipeline

7 Products in Development | **2** Products in Phase 3 | **1** Product in Phase 2

Current Program/Product	Study Indication	Phase 1	Phase 2	Phase 3	Filed
Wave 4*					
Nivolumab+Relatlimab (BMS)	Melanoma				
TAK-881 (Takeda)	Immune				
N6LS bnAb (ViiV)	HIV (treatment)				
Cabotegravir (ViiV)	HIV				
ARGX-117; Empasiprubart (argenx)	Multifocal motor neuropathy				
Undisclosed (Roche)	Undisclosed				
Undisclosed (Chugai)	Undisclosed				

* Wave 4 includes products with potential to launch by 2027, based on 4.5 -5 years from SC first in human, to launch

Halozyme Developed and Clinically Tested the FIRST High Volume Auto-Injector Delivering 10 mL SC in Just 30 Seconds

What made this uniquely possible?

ENHANZE® Technology. Alliance. Solutions. + Halozyme Auto-Injector Technology and Know-How ›

First HVAI Delivering 3-10 mL in <30 seconds.

Results:

- 100% success
- Well tolerated
- High patient acceptance

Halozyme Expertise

- ✓ Full pharma and device development capabilities
- ✓ Multiple combination product approvals (US, EU)
- ✓ Emergency use and high-viscosity specialty

Capital Allocation Priorities

Invest to Maximize Revenue Growth and Durability

ENHANZE®

HVAI and auto-injector innovation

Return Capital to Shareholders

Initiated $250M ASR in 4Q23 to be completed in 2024, for a total of $400M deployed in 2023

Announced Board approval for new $750M share buyback program in February 2024

Returned $1.3B (inclusive of ongoing $250M ASR) to shareholders in share buybacks over the past 5 years

Identify Opportunities for External Growth

Continue to evaluate opportunities to accelerate and extend revenue

4Q 2023 Financial Highlights

$ in Millions, except EPS (unaudited)

	4Q 2023	4Q 2022	% Change
Royalties	$122.1	$106.0	15%
Product sales, net	$79.6	$61.2	30%
Collaboration revenues	$28.4	$14.4	98%
Total Revenues	**$230.0**	**$181.5**	**27%**
Cost of sales	$52.3	$42.1	24%
Amortization of intangibles	$17.8	$4.6	290%
R&D expense	$21.3	$22.6	(6)%
SG&A expense	$37.6	$37.7	-
Total Operating Expenses	**$129.0**	**$107.0**	**21%**
Operating income	$101.0	$74.5	36%
Net Income	**$85.4**	**$57.7**	**48%**
EBITDA	$121.7	$81.6	49%
Adjusted EBITDA	**$121.7**	**$83.0**	**47%**
GAAP diluted EPS	$0.65	$0.42	55%
Non-GAAP Diluted EPS	**$0.82**	**$0.48**	**71%**

FY 2023 Results

$ in Millions, except EPS (unaudited)

	FY 2023	FY 2022	% Change
Royalties	$447.9	$360.5	24%
Product sales, net	$300.9	$191.0	57%
Collaboration revenues	$80.5	$108.6	(26%)
Total Revenues	**$829.3**	**$660.1**	**26%**
Cost of sales	$192.4	$139.3	38%
Amortization of intangibles	$73.8	$43.1	71%
R&D expense	$76.4	$66.6	15%
SG&A expense	$149.2	$143.5	4%
Total Operating Expenses	**$491.7**	**$392.6**	**25%**
Operating income	$337.6	$267.5	26%
Net Income	**$281.6**	**$202.1**	**39%**
EBITDA	$435.6	$314.5	39%
Adjusted EBITDA	**$426.2**	**$359.0**	**19%**
GAAP diluted EPS	$2.10	$1.44	46%
Non-GAAP Diluted EPS	**$2.77**	**$2.21**	**25%**

2024 Financial Guidance Highlights

	2023	2024 Guidance[1]	
Total Revenue	$829M	**$915M - $985M**	• 10-19% YOY growth • Total collaboration revenue expected to increase compared to 2023 inclusive of new deals • Product sales growth from XYOSTED®; projecting API sales decline due to price reductions resulting from yield improvements • Milestones and API sales to be substantially weighted in the second half of the year
Royalty Revenue	$448M	**$500M - $525M**	• 12-17% YOY growth • Continued DARZALEX® SC and Phesgo® Wave 2 growth • Wave 3 uptake driven by VYVGART® Hytrulo and Tecentriq® SC • Sequential growth to flatten in the first and second quarter, growth sequentially thereafter
Adjusted EBITDA	$426M	**$535M - $585M**	• 26-37% YOY growth • YoY growth driven by gross margin expansion from revenue mix • Adjusted EBITDA margin increasing from 51% in 2023 to 58-59% in 2024
Non-GAAP Diluted EPS	$2.77	**$3.55 - $3.90**	• 28-41% YOY growth • YoY growth driven by gross margin expansion from revenue mix and full year impact of 2023 share repurchase activity

[1] Growth rates calculated from 2023 actuals to low end of 2024 range and high end of 2024 range

Our Vision

Today

Many breakthrough therapies **require the patient's life to fit the treatment**



Our Vision

Breakthrough therapies will **fit the patient's life**

Subcutaneous delivery with ENHANZE can result in…

Decreased treatment burden
Treatment from hours to minutes[3]

Lower infusion related reactions (IRRs)[1]

Enable possibility of new treatment sites
Home, doctor's office, community hospital[4]

85-90% of patients prefer SC versus IV (Herceptin®, Phesgo®[2])

Halozyme

[1] Lancet Haematol. "Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomised, phase 3 trial"; 2020.
[2] Pivot X, Gligorov J, Müller V, et al. "Patients' Preference for SC vs. IV", Annals of Oncology, 2014; 3:4. Phesgo® Prescribing Information.
[3] Phesgo® Prescribing Information and DARZALEX® Faspro Prescribing Information.
[4] VYVGART® Hytrulo Prescribing Information in Europe.

Looking Ahead: 2024 and Beyond

$ in Millions, except EPS (unaudited)

	2023 Actual	2024 Guidance	2025	2026	2027	2028	2023-2028 CAGR[7]
Royalties[1]	447.9	500 – 525	595 – 620	750 – 790	975 – 1,025	1,000 – 1,050	18%
Product Sales[2]	300.9	285 – 300	315 – 335	385 – 415	410 – 455	435 – 480	9%
Collaboration Revenue[3]	80.5	130 – 160	130 – 160	130 – 160	130 – 160	130 – 160	12%
Total Revenue	829.3	915 – 985	1,040 – 1,115	1,265 – 1,365	1,515 – 1,640	1,565 – 1,690	14%
Adjusted EBITDA[4]	426.2	535 – 585	655 – 705	855 – 935	1,070 – 1,195	1,125 – 1,250	23%
Adjusted EBITDA Margin[5]	51%	58% – 59%	63% – 63%	68% – 68%	71% – 73%	72% – 74%	7%
Non-GAAP Diluted EPS[6]	2.77	3.55 – 3.90	4.10 – 4.50	5.30 – 5.80	6.70 – 7.30	6.90 – 7.50	21%

1 Royalty projections based on approved ENHANZE® products and assumes global approval and launches of Vyvgart® Hyrulo CIDP, Atezolizumab SC in US, Ocrelizumab SC, Nivolumab SC and Amivatamab SC and all approved Auto-Injector products. Assumes impact of pending or issued co-formulation patents. Does not include the impact of Halozyme pending patents. Innovator revenues based on Evaluate Ltd analyst-based estimates as of December 2023 when available otherwise based on select analyst estimates. Conversion rates based on Halozyme internal projections. Projected royalty revenue is not risk-adjusted. Royalty rate on average mid-single digit range across all products.

2 Product sales projections based on Xyosted® and Hylenex® commercial products and sales of ENHANZE® API and auto-injector devices to collaboration partners

3 Collaboration revenue includes development, regulatory, and commercial milestones for certain ENHANZE® and SVAI development programs currently advancing and projected new deals

4 Adjusted EBITDA projections represent earnings before interest income/expense, tax, and depreciation and amortization with adjustments for one-time, non-recurring items

5 Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by Total Revenue

6 Non-GAAP Diluted EPS excludes impact of potential future share repurchases

7 2023-2028 CAGR % is calculated from 2023 actual to 2028 midpoint

All projections exclude the impact of potential future M&A

Halozyme

GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

$ in Thousands (unaudited)

	Three Months Ended December 31,	
	2023	2022
GAAP Net Income	**$ 85,388**	**$ 57,702**
Adjustments		
Investment and other income	(5,360)	(852)
Interest expense	5,220	4,570
Income tax expense	15,787	13,089
Depreciation and amortization	20,693	7,114
EBITDA	**121,728**	**81,623**
Adjustments		
Transaction costs for business combinations[(1)]	—	1,391
Adjusted EBITDA	**$ 121,728**	**$ 83,014**

(1) Amounts represent incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year acquisition of Antares Pharma, Inc. (“Antares”).

Halozyme

GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

$ in Thousands (unaudited)	Twelve Months Ended December 31,	
	2023	2022
GAAP Net Income	**$ 281,594**	**$ 202,129**
Adjustments		
Investment and other income	(16,317)	(1,046)
Interest expense	18,762	16,947
Income tax expense	66,735	46,789
Depreciation and amortization	84,856	49,641
EBITDA	**435,630**	**314,460**
Adjustments		
Gain on changes in fair value of contingent liability[(1)]	(13,200)	—
Inventory write-off[(2)]	3,509	—
Transaction costs for business combinations[(3)]	278	21,934
Severance and share-based compensation acceleration expense[(4)]	—	22,552
Adjusted EBITDA	**$ 426,217**	**$ 358,946**

(1) Amount relates to fair value gain on contingent liability due to the due to the termination of the TLANDO license agreement in September 2023 ("TLANDO Termination").

(2) Amount relates to inventory write-off due to TLANDO Termination and amortization of the inventory step-up associated with purchase accounting for the prior year Antares acquisition.

(3) Amounts represent incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year Antares acquisition.

(4) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.

GAAP to Non-GAAP Reconciliation: Diluted EPS

(unaudited)

	Three Months Ended December 31,	
	2023	2022
GAAP Diluted EPS	**$ 0.65**	**$ 0.42**
Adjustments		
Share-based compensation	0.07	0.05
Amortization of debt discount	0.01	0.01
Amortization of intangible assets	0.14	0.03
Amortization of inventory step-up at fair value[(1)]	—	(0.01)
Prior income tax benefit adjustments	(0.04)	—
Income tax effect of above adjustments[(2)]	(0.01)	(0.03)
Non-GAAP Diluted EPS	**$ 0.82**	**$ 0.48**
GAAP & Non-GAAP Diluted Shares	**131,035**	**138,601**

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

(1) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.

(2) Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items.

GAAP to Non-GAAP Reconciliation: Diluted EPS

(unaudited)	Twelve Months Ended December 31,	
	2023	2022
GAAP Diluted EPS	**$ 2.10**	**$ 1.44**
Adjustments		
Inducement expense related to convertible notes	—	0.02
Share-based compensation	0.27	0.17
Amortization of debt discount	0.05	0.06
Amortization of intangible assets	0.53	0.31
Transaction costs for business combinations[1]	—	0.16
Severance and share-based compensation acceleration expense[2]	—	0.16
Amortization of inventory step-up at fair value[3]	0.02	0.06
Realized loss from marketable securities[4]	—	0.01
Prior income tax benefit adjustments	(0.04)	—
TLANDO Related Adjustments		
Gain on changes in fair value of contingent liability[5]	(0.10)	—
Inventory write-off[5]	0.03	—
Impairment charge of TLANDO product rights intangible assets[5]	0.02	—
Income tax effect of above adjustments[6]	(0.12)	(0.17)
Non-GAAP Diluted EPS	**$ 2.77**	**$ 2.21**
GAAP & Non-GAAP Diluted Shares	**134,197**	**140,608**

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

(1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year Antares acquisition.

(2) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.

(3) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.

(4) Amount represents a realized loss from the sale of our marketable securities to finance the prior year acquisition of Antares.

(5) Amounts relate to a fair value gain on contingent liability, inventory write-off and impairment of TLANDO product rights intangible assets due to the TLANDO Termination.

(6) Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items.

Halozyme

GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS

	Twelve Months Ended December 31,	
	2023	2022
GAAP Net Income	**$ 281,594**	**$ 202,129**
Adjustments:		
Inducement expense related to convertible notes	—	2,712
Share-based compensation	36,620	24,397
Amortization of debt discount	7,304	7,839
Amortization of intangible assets	71,266	43,148
Transaction costs for business combinations[1]	278	21,934
Severance and share-based compensation acceleration expense[2]	—	22,552
Amortization of inventory step-up at fair value[3]	2,560	8,931
Realized loss from marketable securities[4]	—	1,727
Prior year income tax benefit[)	(5,375)	—
TLANDO Related Adjustments:		
Gain on changes in fair value of contingent liability[5]	(13,200)	—
Inventory write-off[5]	3,509	—
Impairment charge of TLANDO product rights intangible assets[5]	2,507	—
Income tax effect of above adjustments[6]	(15,753)	(24,025)
Non-GAAP Net Income	**$ 371,310**	**$ 311,344**
GAAP Diluted EPS	**$ 2.10**	**$ 1.44**
Adjustments		
Inducement expense related to convertible notes	—	0.02
Share-based compensation	0.27	0.17
Amortization of debt discount	0.05	0.06
Amortization of intangible assets	0.53	0.31
Transaction costs for business combinations[1]	—	0.16
Severance and share-based compensation acceleration expense[2]	—	0.16
Amortization of inventory step-up at fair value[3]	0.02	0.06
Realized loss from marketable securities[4]	—	0.01
Prior income tax benefit adjustments	(0.04)	—
TLANDO Related Adjustments		
Gain on changes in fair value of contingent liability[5]	(0.10)	—
Inventory write-off[5]	0.03	—
Impairment charge of TLANDO product rights intangible assets[5]	0.02	—
Income tax effect of above adjustments[6]	(0.12)	(0.17)
Non-GAAP Diluted EPS	**$ 2.77**	**$ 2.21**
GAAP & Non-GAAP Diluted Shares	**134,197**	**140,608**

1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year Antares acquisition.
2) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.
3) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.
4) Amount represents a realized loss from the sale of our marketable securities to finance the prior year acquisition of Antares.
5) Amounts relate to a fair value gain on contingent liability, inventory write-off and impairment of TLANDO product rights intangible assets due to the TLANDO Termination.
6) Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items.

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

Halozyme